Xenetic Biosciences (NASDAQ:XBIO) Issues Quarterly Earnings Results, Misses Expectations By $0.14 EPS

Xenetic Biosciences (NASDAQ:XBIO) announced its earnings results on Tuesday. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.14), Zacks reports. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 47.21%. The business had revenue of $0.61 million for the quarter, compared to the consensus estimate of $0.75 million.

Xenetic Biosciences Price Performance

Shares of NASDAQ XBIO traded down $0.05 during mid-day trading on Thursday, reaching $3.60. 10,227 shares of the company traded hands, compared to its average volume of 11,224. Xenetic Biosciences has a fifty-two week low of $2.78 and a fifty-two week high of $5.20. The firm has a market cap of $5.55 million, a PE ratio of -1.47 and a beta of 2.25. The stock has a fifty day simple moving average of $3.89 and a 200-day simple moving average of $3.93.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “neutral” rating on shares of Xenetic Biosciences in a research report on Tuesday, August 20th.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.